↓ Skip to main content

Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon

Overview of attention for article published in Journal of Molecular Medicine, September 2007
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#45 of 1,579)
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

blogs
1 blog
twitter
1 X user
patent
6 patents
facebook
2 Facebook pages

Citations

dimensions_citation
96 Dimensions

Readers on

mendeley
67 Mendeley
Title
Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon
Published in
Journal of Molecular Medicine, September 2007
DOI 10.1007/s00109-007-0248-4
Pubmed ID
Authors

Angelo A. Izzo, Gabriella Aviello, Stefania Petrosino, Pierangelo Orlando, Giovanni Marsicano, Beat Lutz, Francesca Borrelli, Raffaele Capasso, Santosh Nigam, Francesco Capasso, Vincenzo Di Marzo, Endocannabinoid Research Group

Abstract

Colorectal cancer is an increasingly important cause of death in Western countries. Endocannabinoids inhibit colorectal carcinoma cell proliferation in vitro. In this paper, we investigated the involvement of endocannabinoids on the formation of aberrant crypt foci (ACF, earliest preneoplastic lesions) in the colon mouse in vivo. ACF were induced by azoxymethane (AOM); fatty acid amide hydrolase (FAAH) and cannabinoid receptor messenger ribonucleic acid (mRNA) levels were analyzed by the quantitative reverse transcription polymerase chain reaction (RT-PCR); endocannabinoid levels were measured by liquid chromatography-mass spectrometry; caspase-3 and caspase-9 expressions were measured by Western blot analysis. Colonic ACF formation after AOM administration was associated with increased levels of 2-arachidonoylglycerol (with no changes in FAAH and cannabinoid receptor mRNA levels) and reduction in cleaved caspase-3 and caspase-9 expression. The FAAH inhibitor N-arachidonoylserotonin increased colon endocannabinoid levels, reduced ACF formation, and partially normalized cleaved caspase-3 (but not caspase-9) expression. Notably, N-arachidonoylserotonin completely prevented the formation of ACF with four or more crypts, which have been show to be best correlated with final tumor incidence. The effect of N-arachidonoylserotonin on ACF formation was mimicked by the cannabinoid receptor agonist HU-210. No differences in ACF formation were observed between CB(1) receptor-deficient and wild-type mice. It is concluded that pharmacological enhancement of endocannabinoid levels (through inhibition of endocannabinoid hydrolysis) reduces the development of precancerous lesions in the mouse colon. The protective effect appears to involve caspase-3 (but not caspase-9) activation.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Czechia 1 1%
Unknown 65 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 22%
Student > Ph. D. Student 10 15%
Student > Master 8 12%
Student > Doctoral Student 6 9%
Student > Bachelor 5 7%
Other 13 19%
Unknown 10 15%
Readers by discipline Count As %
Medicine and Dentistry 14 21%
Pharmacology, Toxicology and Pharmaceutical Science 10 15%
Biochemistry, Genetics and Molecular Biology 9 13%
Agricultural and Biological Sciences 9 13%
Chemistry 6 9%
Other 5 7%
Unknown 14 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2022.
All research outputs
#1,892,946
of 23,806,312 outputs
Outputs from Journal of Molecular Medicine
#45
of 1,579 outputs
Outputs of similar age
#3,830
of 71,212 outputs
Outputs of similar age from Journal of Molecular Medicine
#1
of 10 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,579 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 71,212 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them